Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avis › Tidsskriftartikel › Forskning › peer review
Pharmacogenetics of lithium long-term treatment : focus on initiation and adaptation mechanisms. / Serretti, Alessandro; Drago, Antonio.
I: Neuropsychobiology, Bind 62, Nr. 1, 2010, s. 61-71.Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avis › Tidsskriftartikel › Forskning › peer review
}
TY - JOUR
T1 - Pharmacogenetics of lithium long-term treatment
T2 - focus on initiation and adaptation mechanisms
AU - Serretti, Alessandro
AU - Drago, Antonio
N1 - Copyright 2010 S. Karger AG, Basel.
PY - 2010
Y1 - 2010
N2 - Bipolar disorder is a common disease with a high impact in terms of personal suffering and socioeconomic burden. The disentanglement of the molecular deregulations that cause this disorder is pivotal to the understanding of its etiology. This will hopefully cast the engineering of new and more favorable treatments. New insights in the molecular aspects of bipolar disorder may be brought by the understanding of the pharmacodynamics of lithium, the first-line treatment for this disease. The mechanisms by which lithium exerts its activity in the central nervous system are not fully clarified: it is hypothesized that lithium may drive acute molecular events whose activation over time triggers long-lasting modifications in critical neuronal nets. These events are associated with long-lasting changes in the expression profile of genes in neurons that are embedded in these crucial nets. The molecular events that are acutely and chronically triggered by lithium will be reviewed here and matched with the evidence that arises from the pharmacogenetics investigations. Moreover, the pharmacogenetics reports that are not strictly associated with the mechanisms that are thought to be acutely and chronically elicited by lithium will be included in the final part of the paper.
AB - Bipolar disorder is a common disease with a high impact in terms of personal suffering and socioeconomic burden. The disentanglement of the molecular deregulations that cause this disorder is pivotal to the understanding of its etiology. This will hopefully cast the engineering of new and more favorable treatments. New insights in the molecular aspects of bipolar disorder may be brought by the understanding of the pharmacodynamics of lithium, the first-line treatment for this disease. The mechanisms by which lithium exerts its activity in the central nervous system are not fully clarified: it is hypothesized that lithium may drive acute molecular events whose activation over time triggers long-lasting modifications in critical neuronal nets. These events are associated with long-lasting changes in the expression profile of genes in neurons that are embedded in these crucial nets. The molecular events that are acutely and chronically triggered by lithium will be reviewed here and matched with the evidence that arises from the pharmacogenetics investigations. Moreover, the pharmacogenetics reports that are not strictly associated with the mechanisms that are thought to be acutely and chronically elicited by lithium will be included in the final part of the paper.
KW - Animals
KW - Antimanic Agents
KW - Bipolar Disorder
KW - Humans
KW - Lithium Compounds
KW - Time Factors
U2 - 10.1159/000314311
DO - 10.1159/000314311
M3 - Journal article
C2 - 20453536
VL - 62
SP - 61
EP - 71
JO - Neuropsychobiology
JF - Neuropsychobiology
SN - 0302-282X
IS - 1
ER -